Bionomics Limited/fi 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Neuphoria Therapeutics Inc. reported a net loss for the quarter ended March 31, 2026, and is undergoing a strategic review, pausing its PTSD program.
Neuphoria Therapeutics Inc. reported a significant net loss increase, discontinued its SAD program after a Phase 3 trial failure, and initiated a strategic review amidst an unsolicited acquisition offer.
Neuphoria Therapeutics achieved a profitable quarter due to milestone payments from collaborations, particularly with Merck & Co., while continuing to advance its clinical programs.
10-Q: Neuphoria Therapeutics Reports Q2 2025 Results, Highlights Redomiciliation and Milestone Payment
Neuphoria Therapeutics reports its Q2 2025 results, marking its redomiciliation to the US and highlighting a significant milestone payment from Merck.
Bionomics Limited reports a net loss of $0.8 million for the quarter ended September 30, 2024, and provides an update on its clinical programs and financial position.